QTTB (Q32 Bio) חוב לטווח קצר להון

The Q32 Bio Inc. (QTTB) price chart reflects dynamics driven by the development of advanced targeted biologics and interleukin inhibitors, with the metric standing at 0.01. The business focuses on treating innate immunity pathologies within the global immunology market. However, geopolitical tensions and sanctions are severely hindering the logistics of biomaterials, complicating the execution of large-scale clinical trials for new drugs.

The short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year relative to shareholders' equity, reflecting current financial stability and liquidity risk. For Q32 Bio Inc. (QTTB), amid fierce competition with pharma behemoths, the short-term leverage chart serves as an indicator of the company's ability to fund development without a critical debt burden, determining the fundamental viability of the business.